Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Trial Profile

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Brimapitide (Primary)
  • Indications Sensorineural hearing loss
  • Focus Registrational; Therapeutic Use
  • Acronyms ASSENT
  • Sponsors Auris Medical
  • Most Recent Events

    • 08 Dec 2017 Planned End Date changed from 1 Jun 2018 to 1 Mar 2018.
    • 08 Dec 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Mar 2018.
    • 08 Dec 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top